Received: 29 April 2021
Accepted: 13 December 2021
First Online: 3 January 2022
: The study was approved by the Ethics committee (Comité de protection des personnes Ile de France XI) on January 15, 2009 (ref 09006) and by the French National Agency for Medicines and Health Products (ANSM) on February 6, 2009 (ref B81333–40) (ClinicalTrials.gov NCT01065909). All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: LB appeared/appears as principal or co-investigator of several clinical trials from different SPONSORS: Novartis, Actelion, Alnylam Pharmaceuticals, IONIS Pharmaceutical, Takeda, Novonordisk, Shire, Boehringer. Received fees from Sanofi-Genzyme. SZ, EB, EC, JSV and ED declare that they have no competing interests.